PrimeLink Bio to Showcase Dual-Payload ADC Platform Data at 2026 AACR

PrimeLink Bio will present preclinical research findings of its self-developed novel dual-payload ADC technology platform in a poster session at the American Association for Cancer Research (AACR) Annual Meeting, taking place from April 17-22, 2026, in San Diego, USA.

Details of the presentation are outlined below:

Title: PLB-015, a novel anti-HER2 dual payload ADC for the treatment of HER2 positive solid tumors

Location：Poster Section 52

Session Date and Time：4/19/2026, 14:00 PM ~ 17:00 PM

Contact us

contact@primelinkbio.com

About AACR

Founded in 1907, the American Association for Cancer Research (AACR) is the world's oldest and largest professional organization dedicated to cancer research. The AACR Annual Meeting stands as the premier academic conference in the global cancer research community, attracting tens of thousands of scientists, clinicians, and pharmaceutical industry representatives from around the world each year. The meeting encompasses cutting-edge fields including cancer biology, translational medicine, clinical trials, and cancer immunotherapy, serving as a vital platform for unveiling major research breakthroughs and fostering international collaboration.

About PrimeLink Bio

PrimeLink Bio, founded in July 2021 by Dr. Yin Mao, is an innovative biopharmaceutical enterprise dedicated to developing next-generation antibody-drug conjugates (ADCs). Guided by the core philosophy of "tailoring the optimal ADC structure for each target," the company has independently developed a flexible, modular technology platform named ENHANMIX®. Featuring high hydrophilicity, compatibility, and flexibility, ENHANMIX® provides a novel approach to addressing safety and resistance challenges in ADC therapeutics.

Leveraging its innovative ENHANMIN®  and differentiated product pipeline, PrimeLink Bio has established a robust portfolio encompassing single-target ADCs and novel modalities such as bispecific ADCs and dual-payload ADCs. The company has secured investments from leading domestic and international investment institutions including Vertex Ventures, Fosun Pharma, Kaitai Capital, Longmen Capital, and Elikon Venture, raising cumulative financing exceeding RMB 200 million. PrimeLink Bio has also been honored with multiple prestigious awards, including the "Top 100 Chinese Pharmaceutical Innovation Value Discovery Companies 2022-2023," National "Technology-based SME," Shenzhen "Innovative SME," "Specialized and Innovative SME," and "Seed Unicorn Enterprise" designations, as well as "Outstanding Enterprise" at the 13th China Innovation and Entrepreneurship Competition.

Moving forward, PrimeLink Bio will continue to evolve its platform technology and advance its product pipeline to benefit cancer patients worldwide.

About PLB-015

PLB-015 is a novel anti-HER2 dual-payload ADC developed by PrimeLink Bio based on its proprietary dual-payload ADC technology platform, featuring a TOP1 inhibitor and an ATR inhibitor as its dual payloads, designed to overcome resistance to TOP1 inhibitors. Preclinical studies have demonstrated that PLB-015 exhibits significant synergistic effects of the TOP1 and ATR inhibitors, showing superior efficacy in Enhertu-resistant models, durable responses, and favorable tolerability in cynomolgus monkeys—fully validating the druggability of PrimeLink Bio's dual-payload ADC technology platform.